NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

癌症單株抗體的全球市場(2021年∼2025年)

Global Cancer Monoclonal Antibodies Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 1023732
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
癌症單株抗體的全球市場(2021年∼2025年) Global Cancer Monoclonal Antibodies Market 2021-2025
出版日期: 2021年06月17日內容資訊: 英文 120 Pages
簡介

癌症單株抗體的市場規模在2021年∼2025年的預測期間內,預計將以8.23%的年複合成長率推移,並成長到331億美元。

本報告提供癌症單株抗體市場相關之本報告提供整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

該市場成長的主要因素有對 ADC 日益增長的需求以及供應商和政府的宣傳活動和倡議。

本報告提供癌症單株抗體市場調查,提供市場概要,市場規模,市場預測,客戶形勢,各類型·各地區的分析,再加上業者情勢和供應商分析等資訊。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2020年
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情況

各類型的市場區隔

  • 市場區隔
  • 各類型比較
  • 裸單株抗體:市場規模與預測(2020年∼2025年)
  • 結合及雙特異性單株抗體:市場規模與預測(2020年∼2025年)
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 各地區形勢市場機會
  • 市場成長促進因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Johnson and Johnson Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA

附錄

目錄
Product Code: IRTNTR45482

Technavio has been monitoring the cancer monoclonal antibodies market and it is poised to grow by $ 33.1 bn during 2021-2025, progressing at a CAGR of 8.23% during the forecast period. Our report on cancer monoclonal antibodies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in demand for ADCs and awareness and initiatives taken by vendors and government. In addition, increase in demand for ADCs is anticipated to boost the growth of the market as well.

The cancer monoclonal antibodies market analysis includes the type segment and geographic landscape.

Technavio's cancer monoclonal antibodies market is segmented as below:

By Type

  • Naked monoclonal antibodies
  • Conjugated and bi-specific monoclonal antibodies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the strong R&D pipelineas one of the prime reasons driving the cancer monoclonal antibodies market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer monoclonal antibodies market covers the following areas:

  • Cancer monoclonal antibodies market sizing
  • Cancer monoclonal antibodies market forecast
  • Cancer monoclonal antibodies market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer monoclonal antibodies market vendors that include Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA. Also, the cancer monoclonal antibodies market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Type
    • Market segments
    • Comparison by Type
    • Naked monoclonal antibodies - Market size and forecast 2020-2025
    • Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025
    • Market opportunity by Type
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bristol Myers Squibb Co.
    • F. Hoffmann La Roche Ltd.
    • Johnson and Johnson Inc.
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations
  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Naked monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
  • 24: Naked monoclonal antibodies - Year-over-year growth 2020-2025 (%)
  • 25: Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
  • 26: Conjugated and bi-specific monoclonal antibodies - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share By Geographical Landscape 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity By Geographical Landscape ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Amgen Inc. - Overview
  • 48: Amgen Inc. - Business segments
  • 49: Amgen Inc. - Key offerings
  • 50: Amgen Inc. - Key customers
  • 51: Amgen Inc. - Segment focus
  • 52: Astellas Pharma Inc. - Overview
  • 53: Astellas Pharma Inc. - Product and service
  • 54: Astellas Pharma Inc. - Key offerings
  • 55: Astellas Pharma Inc. - Key customers
  • 56: Astellas Pharma Inc. - Segment focus
  • 57: AstraZeneca Plc - Overview
  • 58: AstraZeneca Plc - Product and service
  • 59: AstraZeneca Plc - Key offerings
  • 60: AstraZeneca Plc - Key customers
  • 61: AstraZeneca Plc - Segment focus
  • 62: Bristol Myers Squibb Co. - Overview
  • 63: Bristol Myers Squibb Co. - Product and service
  • 64: Bristol Myers Squibb Co. - Key offerings
  • 65: Bristol Myers Squibb Co. - Key customers
  • 66: Bristol Myers Squibb Co. - Segment focus
  • 67: F. Hoffmann La Roche Ltd. - Overview
  • 68: F. Hoffmann La Roche Ltd. - Business segments
  • 69: F. Hoffmann La Roche Ltd. - Key offerings
  • 70: F. Hoffmann La Roche Ltd. - Key customers
  • 71: F. Hoffmann La Roche Ltd. - Segment focus
  • 72: Johnson and Johnson Inc. - Overview
  • 73: Johnson and Johnson Inc. - Business segments
  • 74: Johnson and Johnson Inc. - Key offerings
  • 75: Johnson and Johnson Inc. - Key customers
  • 76: Johnson and Johnson Inc. - Segment focus
  • 77: Merck and Co. Inc. - Overview
  • 78: Merck and Co. Inc. - Business segments
  • 79: Merck and Co. Inc. - Key offerings
  • 80: Merck and Co. Inc. - Key customers
  • 81: Merck and Co. Inc. - Segment focus
  • 82: Novartis AG - Overview
  • 83: Novartis AG - Business segments
  • 84: Novartis AG - Key offerings
  • 85: Novartis AG - Key customers
  • 86: Novartis AG - Segment focus
  • 87: Pfizer Inc. - Overview
  • 88: Pfizer Inc. - Business segments
  • 89: Pfizer Inc. - Key offerings
  • 90: Pfizer Inc. - Key customers
  • 91: Pfizer Inc. - Segment focus
  • 92: Sanofi SA - Overview
  • 93: Sanofi SA - Business segments
  • 94: Sanofi SA - Key offerings
  • 95: Sanofi SA - Key customers
  • 96: Sanofi SA - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations